University of Pécs
1367

Art of the Kill: – UV-inactivation

Protein and PCR intact virus for next-gen vaccines, diagnostics, and biodefense.

CHALLENGE

BSL-4 labs are rarer than astronauts. High-containment research is costly, scarce, and inaccessible to most laboratories. Conventional inactivation can damage valuable viral structures. RoLink removes these barriers, potentially reducing handling costs by up to 90% while preserving biological value for research, diagnostics, CBRN preparedness, and vaccines.

SOLUTION

From high-risk viruses to safe, ready-to-use reagents. RoLink's validated UV-C platform preserves viral antigens while eliminating infectivity, enabling lower-containment research, premium laboratory reagents ($500–$6,000/mL), CBRN preparedness, diagnostics, and vaccine development.



BSL-4

BSL-2



INVESTMENT HOOK

90% lower handling costs. $6,000/mL product potential. €1.1M+ secured funding. One scalable UV-C platform unlocking high-value markets in diagnostics, CBRN biodefence, and next-generation vaccines.

WE ARE SEEKING FOR

Seeking $900,000 in growth capital to scale commercial production, establish a second UV-C reactor, launch 10 market-ready viral products, expand international sales, and strengthen quality control, intellectual property, and AI-enabled operations.

THE TEAM



Dr. Roland Hetényi
Founder & CEO
Medical doctor. UV-C technology development, biosafety, business strategy and commercialization.



Dr. Dániel Hanna, MD
Co-owner & Researcher
Medical doctor. Viral purification, and product development.



Dr. Gábor Kemenesi
University of Pécs | Scientific AdvisorDirector, National Laboratory of Virology. Emerging viruses, BSL-4 research and scientific validation.



Balázs Antal Somogyi
University of Pécs | Chief Biosafety Advisor. High-containment operations. BSL-4.

TRL 6
Target: TRL 7 integrated manufacturing platform

TARGET MARKET SIZE USD 60.3 Billion
Global life science reagents market, 2026. Projected to reach USD 78.9B by 2030 (7% CAGR).

PROPRIETARY UV-C PLATFORM
Technology know-how and licensing potential

FUNDING SECURED
€1.1M+Non-dilutive R&D funding secured to develop and validate the platform.

PARTNERSHIPS
3 defence-related EDF projects

COMMERCIAL TRACTION
$100k+Cumulative revenue since 2025, including R&D projects and early sales.

TIME TO MARKET
Already commercializing10 market-ready viral products targeted within 18 months of investment.

COMPETITIVE EDGE
Preserved antigenicity, PCR compatibility, biosafety expertise and scalable production.

Tradition & Innovation

Dr. Hetényi Roland
+36 30 612 4042
roli@rolink.hu